In an interview with The New York Times editorial board that was published on Friday, the 2020 Democratic presidential candidate was asked to explain his “more moderate approach” to cannabis policy when nearly all of his primary opponents, as well as the public, have embraced broad legalization.
“Because I think science matters,” he said. “I mean one of the reasons I’m running against the guy I’m running against is science matters, not fiction.”
He also said that he’s not arguing that marijuana is a gateway drug—something he did indicate might be the case last year, though he walked it back after facing pushback and being attacked for the statement on a debate stage.
“What I’m arguing is there have been studies showing that it complicates other problems if you already have a problem with certain drugs,” Biden said. “So we should just study it and decriminalize it, but study it and find out. Get the medical community to come up with a final definitive answer as to whether or not it does cause it. If it does cause other problems, then make it clear to people. So that’s a place you don’t not engage in the use of it.”
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers